Brawn Laboratories

Key Metrics of Brawn Laboratories

Competitors10identified

About Brawn Laboratories

Sectors

Pharmaceuticals & HealthcareFormulations & Contract Manufacturing

Company details

Operational Areas of Brawn Laboratories

Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing

Company summary

Entity details

CIN—

LEI code—

State code—

PIN code—

Current legal nameBRAWN LABORATORIES

Classification—

Listing status—

Registration no.—

Company age—

PAN—

CountryIndia

City—

State—

Current status—

Date of incorporation—

Registrar of companies—

Authorised capital—

Paid-up capital—

Employee count—

Compliance

Last AGM date—

Last balance sheet—

Next filing dueAOC-4 for FY 2025-26 · 30 Oct 2026

Industry classification

NIC code—

Description of main activity—

Description of business activity—

SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing

Premium

Financials, ratios and risk analysis

Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.

Sign in to continue See plans & pricing

Filing compliance

AGM for FY 2025-2630 Sep 2026 Statutory due date passed

AOC-4 for FY 2025-2630 Oct 2026 Statutory due date · 0 days left

MGT-7 for FY 2025-2629 Nov 2026 Statutory due date · 30 days left

Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.

Vendor checks & payment capacity

Sign in with access to company financials to review vendor evidence.

Credit ratings

ICRA · 08 May 2026 ICRA BB+ Stable outlook · Short term A4+ · Non-cooperating

Change in last 12 months—

Change since first rating on record—since May 2026

Rating actions10 up · 0 down

WatchIssuer not cooperating with ICRA (rating based on limited information)

Rating history

Rating actions

Date	Agency	Action	Long term	Short term	Outlook	Rated amount	Rationale
08 May 2026	ICRA	Non-cooperating	BB+	A4+	Stable	₹151 Cr	View

Incorporated in 1990, BLL is operated and managed by the Gupta family. The company is involved in the pharmaceutical formulation business, catering to markets in India and abroad. Its manufacturing plant in Faridabad (Haryana) produces tablets, capsules, ointments, syrups and injectables. BLL is also establishing two new manufacturing units in Gujarat, one for formulations and one for active pharmaceutical ingredients (API), out of which the formulations plant will commence commercial production by FY2026. The company has also entered into an arrangement with a leading medical equipment company to act as its commission agent. www.icra.in Sensitivity Label : Public Page |1

Borrowings & rated debt

Rated borrowing limits (latest)₹109 Cr

Limits raised0 times0 new facilities rated

Facility mix

Rated facilities

Facility	Type	Previous	Current	Change	Rating	Action	Agency
Rated facility	Other	₹60.0 Cr	₹60.0 Cr	0.0%	—	Other	ICRA
Rated facility	Other	₹49.1 Cr	₹49.1 Cr	0.0%	—	Other	ICRA
Unallocated limits	Other	₹20.0 L	₹20.0 L	0.0%	BB+ (Stable)	Non-cooperating	ICRA

Credit assessment · Manufacturing

Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts

Indicative long-term—

Indicative short-term—

Score—

LiquidityNot assessable

DirectionStableAgency outlook: Stable

ICRA rating · May 2026BB+

Ratios, pillar scores and the indicative rating are part of Premium.

Rating status

Default	No default on record
Issuer cooperation	Not cooperating since 08 May 2026 (5 months)
Credit enhancement	None – standalone rating
Next action stable or better (model)	42%
Information on file	22% · missing: Audited financial statements (last 18 months), Annual results history (3+ years), Liquidity position, Debt obligations and repayment schedule, Capex / investment plans, Auditor details, Shareholding pattern

Indicative assessment from public data using the published methodology factors; not a credit rating.

Borrowing & funding lifecycle

⬇ PDF report ⬇ Excel

Can it borrow more?Further bank funding difficult Next rating action stable or better: 42% (At risk of downgrade) · ML model on 4072 rating histories, AUC 0.666

Rated limits₹151 Cr

Not yet allocated₹0.20 Cr

Extra debt within 2.5× EBITDA—

Interest coverage—

Limit utilisation—

Open bank charges0 · —

Credit outlook model: 42% chance the next rating action is stable or better
Current rating BB+ (below investment grade)
₹0.2 cr of rated limits not yet tied to a lender
Issuer not cooperating with the rating agency

Rated limits by facility

Timeline

08 May 2026 ICRA non-cooperating: BB+ (Stable)Rated limits ₹151 cr ICRA rationale

Lender names, bank charges and audited borrowings are part of Premium.

Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.

Competitors of Brawn Laboratories